tradingkey.logo

Monte Rosa Therapeutics Inc <GLUE.OQ> expected to post a loss of 34 cents a share - Earnings Preview

ReutersMay 5, 2025 12:46 PM
  • Monte Rosa Therapeutics Inc GLUE.OQ GLUE.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • The Boston Massachusetts-based company is expected to report a 1,239.3% increase in revenue to $14.25 million from $1.06 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Monte Rosa Therapeutics Inc is for a loss of 34 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $16.50​, above​ its last closing price of $4.97. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.02

0.23

Beat

1,100

Sep. 30 2024

-0.46

-0.49

-0.29

Beat

40.4

Jun. 30 2024

-0.53

-0.54

-0.43

Beat

20.4​

Mar. 31 2024

-0.57

-0.57

-0.53

Beat

7.5

​​Dec. 31 2023

-0.30

-0.33

-0.58

Missed

-73.3

Sep. 30 2023

-0.72

-0.72

-0.70

Beat

3.3​

Jun. 30 2023

-0.69

-0.70

-0.71

Missed

-1.4

Mar. 31 2023

-0.68

-0.68

-0.65

Beat

4.3

This summary was machine generated May 5 at 12:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI